{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:03:24Z","timestamp":1753891404652,"version":"3.41.2"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771362, 82171397"],"award-info":[{"award-number":["81771362, 82171397"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012655","name":"Qilu Hospital of Shandong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Vaccination remains the most effective measure to prevent SARS-CoV-2 infection and worse outcomes. However, many myasthenia gravis (MG) patients are hesitant to receive vaccine due to fear of worsening.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>MG patients were consecutively enrolled in two MG centers in North China. The \u201cworsening\u201d after vaccination was self-reported by MG patients, and severity was measured with a single simple question. The general characteristics and disease status immediately prior to the first dose were compared between the worsening and non-worsening groups. Independent factors associated with worsening were explored with multivariate regression analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred and seven patients were included. Eleven patients (10.3%) reported worsening after vaccination, including eight patients with mild or moderate worsening and three patients with severe worsening. Only one of them (0.9%) needed an escalation of immunosuppressive treatments. There were significant differences between the worsening and non-worsening groups in terms of Myasthenia Gravis Foundation of America classes immediately before the first dose and intervals since the last aggravation. Precipitating factors might contribute to the worsening in some patients. Logistic regression revealed that only interval since the last aggravation \u22646 months was associated with worsening after SARS-CoV-2 vaccination (<jats:italic>P<\/jats:italic> = 0.01, OR = 8.62, 95% CI: 1.93\u201338.46).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>SARS-CoV-2 vaccines (an overwhelming majority were inactivated vaccines) were found safe in milder Chinese MG patients who finished two doses. Worsening after vaccination was more frequently seen in patients who were presumed as potentially unstable (intervals since last aggravation \u22646 months). However, mild worsening did occur in patients who were presumed to be stable. Precipitating factors should still be sought and treated for better outcome.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.923017","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T06:35:25Z","timestamp":1659681325000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study"],"prefix":"10.3389","volume":"13","author":[{"given":"Hong-Yan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Yuan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Min","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Xian","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection","volume":"27","author":"Patone","year":"2021","journal-title":"Nat Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":":1112","DOI":"10.3390\/vaccines9101112","article-title":"COVID-19 vaccination in patients with myasthenia gravis: A single-center case series","volume":"9","author":"Ruan","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120225","article-title":"Flare of myasthenia gravis induced by COVID-19 vaccines","volume":"436","author":"Ishizuchi","year":"2022","journal-title":"J Neurol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2022.01.013","article-title":"Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis","volume":"32","author":"Lotan","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15348","article-title":"Safety and tolerability of SARS-Cov2 vaccination in patients with myasthenia gravis: a multicenter experience","volume":"29","author":"Farina","year":"2022","journal-title":"Eur J Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.733418","article-title":"To be or not to be vaccinated: That is a question in myasthenia gravis","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25720","article-title":"The utility of a single simple question in the evaluation of patients with myasthenia gravis","volume":"57","author":"Abraham","year":"2018","journal-title":"Muscle Nerve"},{"key":"B8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. task force of the medical scientific advisory board of the myasthenia gravis foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1136\/annrheumdis-2021-221490","article-title":"Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR coronavirus vaccine (COVAX) physician-reported registry","volume":"81","author":"Machado","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22077","article-title":"Safety of influenza and H1N1 vaccinations in patients with myasthenia gravis, and patient compliance","volume":"43","author":"Auriel","year":"2011","journal-title":"Muscle Nerve"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21440","article-title":"Safety of influenza vaccination in patients with myasthenia gravis: a population-based study","volume":"40","author":"Zinman","year":"2009","journal-title":"Muscle Nerve"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.01.007","article-title":"Acetylcholine receptor antibody titers and clinical course after influenza vaccination in patients with myasthenia gravis: A double-blind randomized controlled trial (ProPATIent-trial)","volume":"28","author":"Tackenberg","year":"2018","journal-title":"EBioMedicine"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.01.007","article-title":"A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis","volume":"37","author":"Strijbos","year":"2019","journal-title":"Vaccine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2017.13.4.325","article-title":"The impacts of influenza infection and vaccination on exacerbation of myasthenia gravis","volume":"13","author":"Seok","year":"2017","journal-title":"J Clin Neurol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e15581","DOI":"10.7759\/cureus.15581","article-title":"A case of COVID-19 vaccine causing a myasthenia gravis crisis","volume":"13","author":"Tagliaferri","year":"2021","journal-title":"Cureus"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.923017\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T06:35:27Z","timestamp":1659681327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.923017\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":16,"alternative-id":["10.3389\/fimmu.2022.923017"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.923017","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"article-number":"923017"}}